Mutation enrichment in targeted panels flags immunotherapy-responsive POLE-driven hypermutated microsatellite-stable colorectal cancers.
Routine genetic tests can now identify rare colorectal cancers likely to respond to immunotherapy, expanding treatment options without extra testing.
MSS colorectal cancer accounts for over 80% of metastatic cases and is considered uniformly resistant to immune checkpoint inhibitors, but a small POLE-mutant hypermutated subset may respond. This study demonstrates that routine targeted panel sequencing can flag these patients through mutation enrichment patterns, potentially expanding immunotherapy eligibility without the need for additional assays.
What the study was
- Study design
- retrospective_cohort
- Population
- Microsatellite-stable colorectal cancer patients with targeted panel sequencing
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- NPJ Precis Oncol
Why it surfaced
High-priority: addresses a clinically actionable gap in MSS CRC immunotherapy selection; POLE-mutant MSS CRC is an underserved population with high unmet need; method uses existing clinical infrastructure (targeted panels); NPJ Precision Oncology is a high-impact precision medicine journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.